Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

from PortlandTribune.com 3 months ago

The VENTANA FOLR1 RxDx Assay has received CE Mark approval, identifying ovarian cancer patients compatible with the ELAHERE treatment, marking a significant advancement in diagnostics.
PortlandTribune.comhttps://www.portlandtribune.com/online_features/press_releases/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first/article_5568a6e6-aec9-5ac2-ad3b-afd26c03e0a3.html

This assay is the first widely available immunohistochemistry companion diagnostic in Europe focused on targeting epithelial ovarian cancer patients for ELAHERE therapy.
PortlandTribune.comhttps://www.portlandtribune.com/online_features/press_releases/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first/article_5568a6e6-aec9-5ac2-ad3b-afd26c03e0a3.html

Regulators granted early exemption approval for the test in Germany and Austria, indicating its urgent need and potential to improve patient treatment decisions.
PortlandTribune.comhttps://www.portlandtribune.com/online_features/press_releases/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first/article_5568a6e6-aec9-5ac2-ad3b-afd26c03e0a3.html

ELAHERE is a pioneering antibody-drug conjugate created by AbbVie, specifically aimed at treating FRɑ-positive, platinum-resistant ovarian cancer.
PortlandTribune.comhttps://www.portlandtribune.com/online_features/press_releases/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first/article_5568a6e6-aec9-5ac2-ad3b-afd26c03e0a3.html

Read at PortlandTribune.com

#ovarian-cancer #elahre #companion-diagnostics #folate-receptor-1 #roche

Collection

[

...

]